Search

for
Search:

Research

5 / 1000+ results

research IMMUNOLOGICAL AND SOME BIOLOGICAL BIOMARKERS INVESTIGATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

March 2022

This study found that all examined biomarkers and clinical features were elevated in systemic lupus erythematosus patients, particularly ANA and Anti-dsDNA autoantibodies, but no single biomarker was sensitive or specific enough for diagnosis.

research The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

213 citations , June 2017 in “Rheumatology”

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

research Lupus erythematosus: systemic and cutaneous manifestations

144 citations , September 2006 in “Clinics in Dermatology”

This article outlines manifestations of systemic lupus erythematosus, noting rapid joint symptom improvement with corticosteroids and antimalarial drug responsiveness for skin symptoms, and links anti-Ro with photosensitive rash and subacute lupus.

research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study

July 2025 in “Journal of Investigative Dermatology”

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

research Systemic immunotherapies

May 2023 in “Elsevier eBooks”

This study reports that while systemic immunotherapies are often used for immune-mediated hair loss, they may also be considered for treating androgenetic alopecia when it coexists with immune-related conditions like alopecia areata.

View more "systemic biologics" in research →

Community Join

5 / 1000+ results

community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

110 upvotes 2 years ago

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

community Found a slide summary for PP405

35 upvotes 5 months ago

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

community Has anyone find a way to stop/limit ru58841 to go systematic ?

in Finasteride/Dutasteride 4 upvotes 1 year ago

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

community South Korea is debating whether hair loss should be covered by public healthcare. That alone says a lot about how we still misunderstand hair loss.

67 upvotes 7 months ago

South Korea is debating whether hair loss treatments should be covered by public healthcare, highlighting the issue's impact on mental health and social functioning. The discussion centers on whether hair loss should be classified as a medical condition rather than a cosmetic issue, considering its psychological effects and the biological processes involved.

community Dermarolling is a bit sad innit?

in Microneedling 232 upvotes 4 years ago

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

View more "systemic biologics" in community →